[
  {
    "ts": "2026-01-06T11:25:27+00:00",
    "headline": "Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win",
    "summary": "While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.",
    "url": "https://www.clinicaltrialsarena.com/news/zenas-biopharma-obexelimab-phase-iii-obexelimab-igg4-rd/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "e03af6fe-1c09-39ed-961f-a3753a173757",
      "content": {
        "id": "e03af6fe-1c09-39ed-961f-a3753a173757",
        "contentType": "STORY",
        "title": "Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win",
        "description": "",
        "summary": "While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.",
        "pubDate": "2026-01-06T11:25:27Z",
        "displayTime": "2026-01-06T11:25:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/8e39c24b3ce201125a3ee403250dc00f",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "Zenas BioPharma's stock value has dropped more than 50% following a Phase III readout for its lead autoimmune asset",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OMWjMTStxNoiI4lJrg.38w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/8e39c24b3ce201125a3ee403250dc00f.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_1scDCV6aQ_QhofeJwL8KA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/8e39c24b3ce201125a3ee403250dc00f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/zenas-biopharma-obexelimab-phase-iii-obexelimab-igg4-rd/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zenas-stock-drops-51-despite-112527629.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ZBIO"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-06T14:00:00+00:00",
    "headline": "AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE",
    "summary": "Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.",
    "url": "https://finance.yahoo.com/news/amgen-acquires-dark-blue-therapeutics-140000878.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "313e4538-30c5-3a6d-9f66-cd4f7f0a9239",
      "content": {
        "id": "313e4538-30c5-3a6d-9f66-cd4f7f0a9239",
        "contentType": "STORY",
        "title": "AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE",
        "description": "",
        "summary": "Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.",
        "pubDate": "2026-01-06T14:00:00Z",
        "displayTime": "2026-01-06T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d",
          "originalWidth": 400,
          "originalHeight": 98,
          "caption": "Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9xF64eSNrBTdXVSUBRIisA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d.cf.webp",
              "width": 400,
              "height": 98,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LmrL8PQB2Q2cD.YsureBSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dd88fc63427022d71ca8183432abc09d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-acquires-dark-blue-therapeutics-140000878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-acquires-dark-blue-therapeutics-140000878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]